NCT06130280招募中2 期
Ablative Dose Single Fraction MRguided Colorectal Liver Metastasis SBRT
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 32
- 试验地点
- 14
- 主要终点
- Local control rate CRC liver metastasis
研究概览
简要总结
The researchers are doing this study to see if one session of high-dose contrast-enhanced MRI-guided SBRT (stereotactic body radiation therapy) is effective for colorectal cancer that has spread to the liver. The researchers will evaluate how well the study treatment can prevent the liver metastasis from growing and spreading. In addition, they will see whether it causes any side effects and whether there are any characteristics of the research MRI images that can predict response to treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed colorectal carcinoma and evidence of liver metastasis on imaging
- •<=3 liver lesions measurable on contrast enhanced diagnostic MRI with combined size (sum of longest diameters) < 7 cm, and individual size < 5cm. (Subsequent simulation scans will not be used for eligibility assessment. In case of significant change in size exceeding 1cm, the individual participants can continue on the protocol provided all normal tissue contraints are met during planning).
- •Lesion location at least ≥ 2 cm of main, right and left portal vein on the baseline diagnostic MRI. (Subsequent simulation scans will not be used for eligibility assessment. In case of significant change in the distance between the lesion edge and critical structure exceeding 1cm, the individual participants can continue on the protocol provided all normal tissue contraints are met during planning ).
- •Lesion location at least ≥ 1.5 cm of luminal gastrointestinal tract (stomach, small and large bowel). (Subsequent simulation scans will not be used for eligibility assessment. In case of significant change in the distance between the lesion edge and critical structure exceeding 1cm, the individual participants can continue on the protocol provided all normal tissue contraints are met during planning).
- •Lesion location ≥ 0.5 cm of diaphragm
- •Preserved liver function as defined by:
- •Albumin > 2 g/dl
- •< AST/ ALT ≤ 5 x ULN
- •Total Bilirubin ≤ 1.5 x UL
- •Negative serum pregnancy test within 14 days prior to simulation and MRgRT for women of childbearing potential
- •Any prior systemic or hepatic artery intraarterial pump (HAIP) chemotherapy is permitted with a washout of 2 weeks
- •Any prior treatment with FDA-approved or investigational biologics or novel molecularly targeted therapies, including oral or IV formulations, are permitted with a washout of 1 weeks or 4 half-lives, which ever is longer
- •Extrahepatic disease outside the liver is permitted
- •Prior liver resection is permitted provided there is enough liver parenchyma to meet normal tissue contraints
- •Prior liver-directed RT is permitted provided departmental normal tissue constraints for re-irradiation can be met
- •Review by HBP DMT prior to enrollment
排除标准
- •Any history of cirrhosis
- •History of hepatic radioembolization or selective internal radiation therapy (SIRT)
- •History of inflammatory bowel disease that precludes liver RT (at the discretion of the treating radiation oncologist).
- •Current pregnancy or breastfeeding
- •Men or women not using effective contraception.
- •Contraindication to or inability to undergo an MR scan, including, but not limited to the history of MR unsafe implants, any implanted cardiac pacemakers or deffibrilators, history of claustrophobia, and contraindications to Gd-EOB-DTPA contrast agent.
- •Concurrent anti-neoplastic therapy of any kind defined as receipt within 1 week of RT administration
研究组 & 干预措施
MR Guided Single Fraction Stereotactic Body Radiation Therapy (SBRT)
Experimental
Participants will undergo simulation including Gd-EOB-DTPAenhanced MR and planning using minimal margins. Ten days later (+/- 3 days) participants will receive 40Gy single fraction treatment on Elekta Unity using Gd-EOB-DTPA-enhanced MR for image guidance and on-line adaptive replanning.
干预措施: MR Guided Single Fraction Stereotactic Body Radiation Therapy (SBRT) (Radiation)
结局指标
主要结局
Local control rate CRC liver metastasis
时间窗: 1 year
by RECIST
次要结局
未报告次要终点
研究者
研究点 (14)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal FunctionContrast Enhancement in Magnetic Resonance ImagingNCT05061979Bayer24
Unknown
不适用
PINPOINT Feasibility StudyImage Guided RadiotherapyProstate CancerNCT05481372Royal Marsden NHS Foundation Trust14
已完成
1 期
Phase I/II Hypofractionated Radiotherapy for Prostate CancerProstate CancerNCT00214097University of Wisconsin, Madison347
进行中（未招募）
不适用
Trial to Compare MRI-guided Precision Prone Irradiation (PPI) Versus CT-guided Breast IrradiationBreast CancerNCT05731791Weill Medical College of Cornell University17
招募中
不适用
High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT)Breast CancerNCT03954431University of Arizona600